Health Technology

Shionogi & Co., Ltd.

In the news

Japan to shoulder COVID vaccine liability risks Aug 20, 2020
AstraZeneca to supply Japan with 120m COVID-19 vaccine doses Aug 8, 2020
Shionogi to ready COVID-19 vaccines for 30m people Jul 20, 2020
Japan reveals 87 projects eligible for 'China exit' subsidies Jul 18, 2020
Japan and Western drugmakers launch $1bn fund against superbugs Jul 10, 2020

See more articles on Shionogi & Co., Ltd.

Business Summary

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2022	JPY	USD
Revenue	335,138M	2,982.37M
Gross Profit	272,411M	2,424.17M
Operating income	111,480M	992.05M
Income before tax	126,288M	1,123.83M
Net income	114,185M	1,016.12M
EBITDA	127,773M	1,137.04M
Diluted EPS	378.62	3.36
Dividends Per Share	115	1.02
Total Assets	1,150.60B	9,479.72M
Total liabilities	157,052M	1,293.94M
Total equity	975,661M	8,038.40M
Operating cash flow	102,068M	908.29M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	344,667M	367,960M	333,371M	297,177M	335,138M
Gross Profit	270,756M	305,713M	270,117M	238,000M	272,411M
Operating income	115,219M	168,370M	130,609M	95,694M	111,480M
Income before tax	137,378M	174,043M	158,516M	143,018M	126,288M
Net income	108,866M	137,190M	122,193M	111,858M	114,185M
EBITDA	134,226M	187,074M	144,649M	110,403M	127,773M
Diluted EPS	337.42	434.70	395.28	364.88	378.62
Dividends Per Share	82	94	103	108	115
Total Assets	711,463M	938,540M	873,695M	998,992M	1,150.60B
Total liabilities	106,619M	125,125M	108,186M	134,156M	157,052M
Total equity	601,374M	808,774M	765,152M	846,108M	975,661M
Operating cash flow	129,790M	165,000M	131,940M	109,039M	102,068M

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Revenue	3,109.80M	3,318.10M	3,066.16M	2,802.03M	2,982.37M
Gross Profit	2,442.93M	2,756.78M	2,484.38M	2,244.06M	2,424.17M
Operating income	1,039.57M	1,518.28M	1,201.26M	902.28M	992.05M
Income before tax	1,239.51M	1,569.44M	1,457.94M	1,348.49M	1,123.83M
Net income	982.25M	1,237.11M	1,123.86M	1,054.69M	1,016.12M
EBITDA	1,211.07M	1,686.95M	1,330.40M	1,040.97M	1,137.04M
Diluted EPS	3.04	3.92	3.63	3.44	3.36
Dividends Per Share	0.73	0.84	0.94	1.01	1.02
Total Assets	6,689.82M	8,479.37M	8,093.14M	9,040.65M	9,479.72M
Total liabilities	1,002.52M	1,130.46M	1,002.13M	1,214.08M	1,293.94M
Total equity	5,654.66M	7,306.98M	7,087.69M	7,657.08M	8,038.40M
Operating cash flow	1,171.04M	1,487.89M	1,213.51M	1,028.11M	908.29M

Valuation Measures

Mar 2022
PER	19.88
ROA	10.62%
ROE	12.53%
Operating margin	33.26%
Profit margin	34.07%

Key executives

Chairman & President: Isao Teshirogi
Manager-Accounting & Finance: Yuji Hosogai
Senior Executive Officer & GM-Research: Yasuetsu Imune
Senior Executive Officer, Head-R&D: John Keller
Executive Officer & GM-Reliability Guarantee: Takeshi Shiota

Shareholders

Nomura Asset Management Co., Ltd. (6.8%)
Sumitomo Life Insurance Co. (5.9%)
Shionogi & Co., Ltd. (3.8%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.2%)
Sumitomo Mitsui Banking Pension Fund (3.0%)
Nikko Asset Management Co., Ltd. (2.8%)
Daiwa Asset Management Co. Ltd. (2.7%)
Nippon Life Insurance Co. (2.6%)
Capital Research & Management Co. (World Investors) (2.6%)
The Vanguard Group, Inc. (2.4%)

Contact Details

Website:http://www.shionogi.co.jp
Address: 3-1-8 Dosho-machi, Chuo-Ku, Osaka, 541-0045, Japan
Phone: +81.6.6202.2161

Related Companies

Shionogi infectious Disease research Foundation
Shionogi Singapore Pte Ltd.
Shionogi Marketing Solutions Co., Ltd.
Shionogi Pharmacovigilance Center Co., Ltd.
Shionogi Business Partner Co., Ltd.
Shionogi Digital Science Co., Ltd
Shionogi Career Development Center Co., Ltd.
Shionogi TechnoAdvance Research Co., Ltd.
Shionogi BV
Shionogi Pharma Co., Ltd.
Shionogi Healthcare Co. Ltd.
Shionogi & Co., Ltd. /2 Subsidiaries/
Shionogi & Co. Restricted Stock Compensation Plan
Shionogi Healthcare & Co., Ltd.
Pionnier KK
Shionogi USA Holdings, Inc.
Beijing Shionogi Pharmaceutical Technology Ltd.
Shionogi Ltd.
Ezose Sciences, Inc.
Shionogi, Inc.
Shionogi Institute for Medical Science
Aburahi Laboratories
Taiwan Shionogi & Co., Ltd.
Shionogi Pharma Chemicals Co., Ltd.
Shionogi General Service Co., Ltd.
Shionogi Bunseki Center KK
Shionogi Ireland Ltd.
Shionogi Engineering Service Co. Ltd.
UMN Pharma, Inc.
Shionogi Bioresearch Corp.

Competitors

Nabriva Therapeutics Plc
NeuroBo Pharmaceuticals, Inc.
Vaxart, Inc.
Cocrystal Pharma Inc
Trevi Therapeutics, Inc.
Spero Therapeutics, Inc.
TaiMed Biologics Inc.
BioCryst Pharmaceuticals, Inc.
Iterum Therapeutics plc
Atea Pharmaceuticals, Inc.
Vir Biotechnology, Inc.
Acura Pharmaceuticals, Inc.
aTyr Pharma, Inc.
Arbutus Biopharma Corporation
BELLUS Health Inc.
Surface Oncology, Inc.
Terns Pharmaceuticals, Inc.
Zynerba Pharmaceuticals Inc

Last Updated on 28 Nov, 2022